Stock Ratings / Health Care / HCM / options

RCUS (19) PBH (62) BHVN (44) HRMY (86) ⌘ Pro Terminal →

HUTCHMED (China) Limited (HCM) Options Positioning, Max Pain & Unusual Sweeps

$13.15 -3.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.05

HUTCHMED (China) Limited (HCM) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $2.29B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HCM Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HCM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, HUTCHMED (China) Limited (NASDAQ: HCM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $13.15 (-3.24% 1D, market cap $2.29B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, HCM ranks #622 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HCM compare to RCUS and PBH in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HCM carries a Roarable E (34/100 RQD), trailing P/E of 5.2x, gross margin of —, and ROIC of -2.5%. By comparison, RCUS (Arcus Biosciences Inc.) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $2.32B) and PBH (Prestige Consumer Healthcare Inc.) posts a C grade (62/100 RQD, P/E 12.1x, ROIC 13.8%, cap $2.32B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while HRMY leads on capital efficiency (63.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HCM?

▼

Per HCM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001648257), HUTCHMED (China) Limited generated $548.5M in revenue (-13.0% YoY), $456.9M in net income, and -$78.8M in free cash flow against $1.75B in total assets and $68.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $13.05 (-0.77%)🧬 Dilution Drag (+1.36% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HCM)Realized 20D OHLCV Swing Band: ±5.7%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY HCM SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (35% of score)

Altman Z-Score 3.63 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+7/20 pts (21% of score)

SEC Form 4 / 13F Thermometer: 35% Net Buy • Dilution Drag (+1.36% YoY Shares)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$13.50+9.2% Next Q

Q2 (-2Q)

Grade E$14.74-6.4% Next Q

Q3 (-1Q)

Grade E$13.80-4.7% Next Q

Current

Grade E$13.15-8.7% Hist 90D α

Trajectory: D (42) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a HCM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While HCM currently carries a cautious 34/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.69) and Max Pain ($13.81) forces dealer call-delta covering toward $17.15.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HCM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “HCM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±5.7%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (HCM)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for HCM.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HCM)

✓Walkthrough of HCM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HCM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -0.53%🛡️ HOLDING TREND SUPPORT

2026-11-03O $13.59H $13.59L $13.15C $13.15VOL 33.5K

RES: $16.66SUP: $12.73SMA50: $13.69SMA200: $13.20

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HCM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HCM Butterfly Map → + Track HCM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-13.3%/yr Implied 5Y Growth

vs. -13.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HCM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HCM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HCM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HCM)

Health Care Rank #622 of 1016 ⚔️ RCUS vs HCM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HCM vs. RCUS, PBH, BHVN, HRMY)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, HUTCHMED (China) Limited (HCM) ranks #622 by composite RQD confidence (34/100, grade E) and #233 by equity capitalization ($2.29B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while HRMY leads on capital efficiency and profitability with 63.0% ROIC and 77.2% gross margin. HRMY currently holds the highest overall quantitative score in the immediate peer group at 86/100 (A) compared with HCM at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HCM ACTIVE HUTCHMED (China) Limited	E	34/100	5.2x	—	-2.5%	-3.24%	$2.29B	Benchmark Subject
RCUS Arcus Biosciences Inc.	E	19/100	—	—	-35.0%	-2.26%	$2.32B	/rcus-vs-hcm →
PBH Prestige Consumer Healthcare Inc.	C	62/100	12.1x	54.7%	13.8%	+0.64%	$2.32B	/pbh-vs-hcm →
BHVN Biohaven Ltd.	D	44/100	—	—	-35.0%	-6.49%	$2.33B	/bhvn-vs-hcm →
HRMY Harmony Biosciences Holdings Inc.	A	86/100	14.2x	77.2%	63.0%	+0.44%	$2.26B	/hrmy-vs-hcm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001648257

In its most recent audited fiscal period (FY2025, filed 2025-12-31), HUTCHMED (China) Limited (HCM) reported GAAP revenue of $548.5M (-13.0% vs. FY2024 revenue of $630.2M , and -34.5% cumulative change since FY2023) , GAAP net income of $456.9M, operating cash flow of -$64.7M, and free cash flow of -$78.8M (-352.0% YoY). On the balance sheet, HCM closed FY2025 with $1.75B in total assets against $68.2M in total debt (Altman Z-Score: 3.63, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$548.5M	$456.9M	-$64.7M	-$78.8M	$1.75B	$68.2M
FY2024 (FY)	2024-12-31	$630.2M	$37.7M	$497.0K	-$17.4M	$1.27B	$59.4M
FY2023 (FY)	2023-12-31	$838.0M	$100.8M	$219.3M	$219.3M	—	—

3. HCM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HCM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does HCM compare to RCUS and PBH in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for HCM?

Where is HCM trading relative to its 50-day, 200-day, and 52-week technical levels?

HCM last traded at $13.15 (-3.24% on volume of 33,496 shares), positioning the stock -3.94% below its 50-day simple moving average ($13.69) and -0.38% below its 200-day simple moving average ($13.20). Across its 52-week range of $9.77 to $16.33, HCM sits at the 51.5% percentile with a 14-day RSI of 42.4 (NEUTRAL RANGE) and an implied next-earnings move of ±5.7% ($12.40 to $13.90).

HCM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is HCM's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for HCM.

Direct Sub-Reports: HCM RQD Cockpit HCM 12M Forecast HCM Earnings & Move HCM Dividends & DRIP HCM Insiders & 13F HCM Whale Options HCM Profit Sankey HCM News & Why

ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

HCM — HUTCHMED (China) Limited: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:25:57Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, HCM scores 42 out of 100, grade D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars: the Fundamental Cash Engine scores 4/20 (ROIC -2.5%; FCF yield -3.32%), which is the weakest pillar and reflects value destruction and negative free cash flow. Whale 13F Flow scores 9/20 and Insider Conviction scores 7/20, indicating weak smart-money and insider support in the source data. Macro Regime Fit scores 10/20 with a beta of 1.0 and sector sensitivity noted. Forensic Balance Sheet scores 12/20, drawing on an Altman Z of 3.63, a Piotroski F of 4/9, and a debt-to-equity of 0.06; this is the strongest pillar, indicating the balance sheet is less distressed than the cash flow and flow signals. For a prospective investor, the implication is that the low headline P/E of 5.2 (TTM) is not a clean value signal: per the Roarable RQD rating, the cash engine and ownership-flow pillars are weak, so upside depends on the company converting its reported earnings into durable cash, which the source data does not yet show. The balance-sheet pillar offers some downside cushion, but the rating as a whole points to caution rather than conviction.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$548.5M	$-39.2M	$456.9M	N/A	$-78.8M	$71.3M	$68.2M
FY 2024	$630.2M	$-43.7M	$37.7M	N/A	$-17.4M	$154.0M	$59.4M
FY 2023	$838.0M	$18.4M	$100.8M	N/A	$219.3M	N/A	N/A

Per the SEC financials, revenue declined from $838.0M (FY 2023) to $630.2M (FY 2024) and $548.5M (FY 2025), while operating income turned negative in both FY 2024 and FY 2025. FY 2025 net income of $456.9M sits far above operating income of $-39.2M, a gap the source data does not explain. Per the Roarable RQD rating and market data, ROIC is -2.5%, the operating margin is -7.1%, and the gross margin is listed as 0%. The Altman Z-Score is 3.63 and the Piotroski F-Score is 4/9, per the Roarable RQD rating, while the debt-to-equity ratio is 0.06; FY 2025 cash of $71.3M against debt of $68.2M is consistent with a modest, but declining, cash position.

Recent Catalysts & News Wire Analysis

Per the news feed, a Yahoo Finance UK report published in the last hour covers HCM market action and institutional positioning (light: YELLOW, "MARKET WIRE").
Per the news feed, a Yahoo Finance report describes the stock as looking expensive relative to current earnings.
Per the news feed, a Stock Titan report states that a GSK subsidiary closed its HUTCHMED drug deal, with up to $1.185B in milestones possibly to follow; this is the most material catalyst in the source data.
Per the news feed, a MarketBeat report describes shares gapping up.
Per the news feed, a Simply Wall St report analyzes the GSK drug licensing deal's implications for shareholders.
Per the news feed, an ad-hoc-news.de report states the stock trades below a USD 14.87 consensus target.
Risk watch items: the expensive-vs-earnings framing, and the gap between reported net income and operating loss. Proprietary signals: Not available in source data (the Butterfly graph lists none).

Open Questions

What drives the gap between FY 2025 net income of $456.9M and operating income of $-39.2M, and is the net income recurring?
What is the timing and probability of the GSK milestone payments up to $1.185B, and how do they change the FCF trajectory?
What are HCM's product lines, revenue mix, and customer concentration?
Why is gross margin listed as 0%, and what does it imply about cost of revenue?
Who holds the stock institutionally, and what are the recent insider and 13F flows?

HCM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for HUTCHMED (China) Limited (HCM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HCM Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance UK • 17h ago

HUTCHMED (China) Limited (0013.HK) stock price, news, quote and history

Yahoo Finance UK report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 20h ago

HUTCHMED (AIM:HCM) Stock Looks Expensive Relative To Current Earnings

Yahoo Finance report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 23h ago

A GSK subsidiary closes its HUTCHMED (HCM) drug deal; up to $1.185B in milestones may follow.

Stock Titan report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

HUTCHMED (NASDAQ:HCM) Shares Gap Up - Time to Buy?

MarketBeat report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

What HUTCHMED (China) (AIM:HCM)'s GSK Drug Licensing Deal Means For Shareholders

Simply Wall St report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

HUTCHMED (China) stock trades below USD 14.87 consensus target

ad-hoc-news.de report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Lung cancer trial investigator Yi-Long Wu will lead HUTCHMED (HCM)'s November 5 webcast.

Stock Titan report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST www.siam.in • 1d ago

HUTCHMED (HCM) Notches +0.79% Gain — Bulls Tighten Grip 2026-10-18 - Small Cap Breakouts

www.siam.in report covering HUTCHMED (China) Limited (HCM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HCM Bull vs. Bear Conversation Board — What's Your Call at $13.15?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HCM 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $11.96 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is HCM (D- • RQD 42/100) a Buy at $13.59?

Welcome to the HCM (HUTCHMED (China) Limited) Roar Pit. Current RQD Composite is 42/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $11.42 (-16.0%)

Spot @ $13.59

Pump the brakes on HCM — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on HCM, but look at what you are paying: 5.2x trailing P/E with tightening sector spreads. Unless HUTCHMED (China) Limited expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $16.85 (+24.0%)

Spot @ $13.59

HCM cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on HCM, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $13.59 (52-wk range $9.77 - $16.33), any beat on forward guidance forces shorts and underweight funds to chase.